Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELVN-001 Phase 1a/1b study in chronic myeloid leukemia
NL-OMON59556Phase 1Recruiting
- Sponsor
- Enliven Therapeutics
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of relcobatinib in chronic myelogenous leukemia (CML), sponsored by Enliven Therapeutics. Started Jun 2025; status: recruiting.
02
Drugs
relcobatinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NL-OMON59556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59556.